Literature DB >> 19671400

[Herpes zoster incidence in persons above 50 years of age].

Keld Østergaard1, Morten Damgaard, Thomas Birk Kristiansen, Thomas Birk Kristensen, Klaus Gregaard Madsen.   

Abstract

INTRODUCTION: Following the development of herpes zoster vaccines and the potential socio-economic benefits hereof, it is relevant to conduct a study concerning epidemiological aspects of the disease based on a Danish population.
MATERIAL AND METHODS: Structured telephone interviews with 1207 persons above 50 years of age were conducted in order to determine the cumulated incidence proportion of herpes zoster in the age groups 50-66 years, 66-70 years and 71+.
RESULTS: The cumulated incidence proportion of herpes zoster was 8.9%, 12.5%, 16.0% in the age groups 50-65 years, 65-70 years and 71+, respectively. Herpes zoster was positively associated with female sex, hypertension, hypercholesterolemia and prescription medicine; however, only the former remained significant after test in a multiple logistic regression model.
CONCLUSION: Herpes zoster is common among persons who are more than 50 years old and most frequent among women.

Entities:  

Mesh:

Year:  2009        PMID: 19671400

Source DB:  PubMed          Journal:  Ugeskr Laeger        ISSN: 0041-5782


  3 in total

1.  Balanitis is a risk factor for herpes zoster.

Authors:  C-Y Hsu; C-L Lin; C-H Kao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-18       Impact factor: 3.267

2.  The short- and long-term risk of stroke after herpes zoster - a nationwide population-based cohort study.

Authors:  Nandini Sreenivasan; Saima Basit; Jan Wohlfahrt; Björn Pasternak; Tina N Munch; Lars P Nielsen; Mads Melbye
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

3.  Hospital-based herpes zoster diagnoses in Denmark: rate, patient characteristics, and all-cause mortality.

Authors:  Sigrun A J Schmidt; Johnny Kahlert; Mogens Vestergaard; Henrik C Schønheyder; Henrik T Sørensen
Journal:  BMC Infect Dis       Date:  2016-03-01       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.